Experimental chemo combo aims to boost transplant success in MDS

NCT ID NCT03572764

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests CPX-351 (Vyxeos), a two-drug chemotherapy, in 20 adults aged 18-70 with higher-risk myelodysplastic syndrome (MDS) who are eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable, with secondary goals of measuring remission rates and how many patients can proceed to transplant. Researchers will also collect blood, bone marrow, and skin samples to understand how the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (Vyxeos), a combination of two chemotherapy drugs (daunorubicin and cytarabine)
What this could lead to: If this works, it could help more high-risk MDS patients achieve remission and proceed to a stem cell transplant, potentially improving long-term outcomes.
What could go wrong: This is a very early (Phase 1) pilot study with only 20 participants, so results may not apply broadly. Chemotherapy carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.